Wednesday, February 08, 2017 7:40:37 AM
Benitec Biopharma Ltd (ADR) (NASDAQ:BNTC) was basically flat throughout late January, but this week has really started to run, on a couple of updates relating to the company’s pipeline. There looks to be plenty of run room left, even with the recent gains taken into consideration, and here’s what we’re watching for to support this bias.
For those new to the company, Benitec is a development stage biotechnology company working to bring treatments to market within a couple of broad areas in healthcare. It’s two lead sector targets are ocular conditions (diseases that affect the eye and – by proxy – sight) and oncology.
The former of these two targets is the primary driver behind the recent action, and will be the focus of this discussion.
So, the company is developing a drug called BB-201, and this is its lead development asset. It’s targeting a condition called wet age-related macular degeneration (wet AMD). This condition is a very common condition, and is especially prevalent in the elderly. It’s the leading cause of blindness in the US (as well as in the majority of other developed nations) and while there are some treatments on the market right now, they all have their drawbacks.
Benitec is trying to overcome one of these major drawback – administration complexity. Current wet AMD treatments (at least, that is, the effective ones) require what’s called subretinal injection. It’s a complex surgical procedure, requires that patients stay in hospital overnight, and is both expensive and risky. Benitec’s therapy has a very similar mechanism of action to current SOC (it works to help regenerate the lost macular cells at the back of the eye) but, and as per the latest announcement, the it is targeting an administration method of what’s called intravitreal injection – in other words, a shot of medicine injected directly into the eye. Normally, this isn’t possible, as the active ingredient of the drug doesn’t get to the retina, where it is required. As the per the latest announcement, however, Benitec has teamed up with a company called 4D Molecular Therapeutics to create a version of the drug that is delivered by way of a viral vector. The best way to think of a viral vector is a sort of delivery packaging. The company puts the active ingredient into the viral vector, and then the whole package is injected in to the eye. Once in there, the virus carries the drug to the retina, and releases it, where it gets to work.
This method is as yet unavailable, and will make for a procedure that is both cheaper and less risky, as well as likely quicker both procedurally and in terms of time to efficacy.
As yet, there’s not too much information available as to exactly how the system will work, and what’s involved. With that said, the company just announced that it was set to present at the Association for Research in Vision and Ophthalmology (ARVO)-Asia meeting, which will be held in Brisbane on February 5 through February 8. The presentation will address the technology in question, and we are likely going to get some degree of insight into the development timeline for the asset. In other words, a road map for when the trials will kick off, and when we can expect to get some clarity into efficacy.
The bottom line here is that this treatment, if it can reach commercialization, can become the standard of care in a very large space by way of its strategic cost and risk advantage over currently available alternatives. There is a ways to go before said commercialization stage is reached, and with this comes the standard capital risks associated with early stage biotech allocations, but we expect a near term run after the above discussed presentation, and this mitigates some of the risk.
All my posts, comments, and investments are not to be considered investment advice in any way.
Recent BNTC News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/29/2024 08:28:27 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 07/19/2024 08:59:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 09:18:32 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2024 02:22:02 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/29/2024 08:32:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 12:05:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 12:01:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:17:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:13:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:12:19 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 02/26/2024 02:06:56 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/23/2024 09:09:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 01:15:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 01:01:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:15:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/30/2023 12:31:00 PM
- Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference • GlobeNewswire Inc. • 11/17/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 01:03:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:00:49 PM
- Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update • GlobeNewswire Inc. • 11/13/2023 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/20/2023 08:31:26 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/20/2023 10:04:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:29:59 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM